The partnership was formed in September 2024 in response to increasing demand for aseptic filling technologies and processes.
In a press release, ten23 health said the Alliance for RTU was formed in response to an increased need in the market for aseptic filling technologies and processes (1). The platform provides a means of technical exchange on high-quality, ready-to-fill primary packaging between pharmaceutical companies, contract manufacturers, and contract development and manufacturing organizations. ten23 health said its role would be to contribute its experience in development, sterile fill/finish, and testing of sterile drug products using RTU containers.
That experience, the company said, is based on a wide range of customer projects aimed at furthering the development and standardization of RTU container platforms, to improve both efficiency and quality while remaining compliant with regulatory standards (1).
Sterile manufacturing, including fill/finish and packaging services, was top of mind for
“From my vantage point, I truly believe in isolator technology,” Mahler said in the interview. “So, that’s where I think an isolator in cleanroom, Class C, is probably where you would want to go if you’re building new facilities. And I think a lot of struggles are ongoing with a lot of folks where, they're trying to actually make upgrades from a filling environment, and that obviously comes with a cost, with a shutdown, and with a potential risk ... [Sustainability] has been a key question … and how we want to operate from a footprint perspective.”
Prior to Pharmapack Europe in January 2025, Gerresheimer Global Vice-President Sales Pharma & Biopharma Solutions Stefan Verheyden
“[Gerresheimer is] becoming an organization that focuses on solutions in specific domains,” Verheyden said in the interview (3). “We want to make sure … we understand what the market needs, and that we anticipate those needs. And therefore, we think it is very important that we understand very well what happens in specific … disease areas, [for example], chronic disease, … repetitive treatments, oncology, all the diseases where we think a more customized product offering could be of an added value.”
ten23 health, which is financed through a long-term commitment from the international investment company 3i Group, is named after the Avogadro constant (6.022 × 1023), which represents the number of molecules in a sample of one mol (1).
1. ten23 health.
2. Thomas, F.
3. Haigney, S.
